currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

TOKYO, Jan 31, 2025 (BSS/AFP) - Takeda Pharmaceuticals has named Julie Kim as the ... Kim, a US citizen and head of the firm's US business, will next year succeed Christophe Weber who in 2015 became ...

The Japanese pharma company acquired Ariad a year ago for $5.2bn, and the latest, more modest acquisition, shows that Takeda's chief Christophe Weber sees buy-outs as ongoing route to growth.